Innate Pharma
Clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | €15.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (18 %) | (79 %) | 310 % | 5 % | (76 %) | 443 % | 70 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 76 % | (305 %) | 68 % | (8 %) | (374 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (113 %) | (436 %) | (117 %) | (15 %) | (392 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 103 % | 388 % | 104 % | 108 % | 412 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Innate Pharma operates in the biopharmaceutical sector, focusing on the development of immunotherapy drugs for cancer treatment. The company specializes in creating NK cell engagers, which are designed to harness the body's natural immune response to target and destroy cancer cells. Innate Pharma collaborates with major pharmaceutical companies, such as Sanofi, to advance its drug candidates through clinical development. The business model involves research and development, followed by strategic partnerships and licensing agreements to commercialize its therapies. Revenue is generated through milestone payments and royalties from these collaborations. Innate Pharma primarily serves the oncology market, aiming to provide innovative solutions for unmet medical needs in cancer care. The company is publicly traded on Euronext Paris, which provides it with access to capital markets to fund its research initiatives.
Keywords: biopharmaceutical, immunotherapy, cancer, NK cell engagers, oncology, drug development, partnerships, licensing, milestone payments, Euronext Paris.